Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

This article is part of the supplement: 35te Tagung der Pathologen am Oberrhein/35th Meeting of Pathologists of the Upper Rhine Region (PATOR)

Open Access Oral presentation

Immunohistochemical detection of micrometastasis and disseminated tumor cells in microscopically tumor free lymph nodes

H Adams* and S Dirnhofer

  • * Corresponding author: H Adams

Author affiliations

Institut für Pathologie, Universität Basel, Switzerland

For all author emails, please log on.

Citation and License

Diagnostic Pathology 2007, 2(Suppl 1):S2  doi:10.1186/1746-1596-2-S1-S2

The electronic version of this article is the complete one and can be found online at:


Published:14 March 2007

© 2007 Adams and Dirnhofer; licensee BioMed Central Ltd.

Oral presentation

Frequency and clinical relevance of micrometastasis (pN1 mi) and disseminated tumor cells (pN0i+) in carcinoma patients are controversially debated or unclear. Thus we immunohistochemically examined the lymph nodes of 422 pN0 classified patients (conventional light microscopy) between November 2004 and March 2006, using the cytokeratin (CK)-22 antibody.

In 13 cases (3%), we found previously undetected micrometatasis (pN1 mi) and 84 cases (20%) were positive for disseminated tumor cells, discovered by immunohistochemistry.

In all cases in which micrometastasis was found, it was only present in one of the lymph nodes examined, whereas isolated tumor cells were found in up to five nodes from one patient. Cases with such findings are mainly breast and colon cancers (pN0 i+ in colorectal carcinomas: n = 39, breast: n = 25, other entities together: n = 19; micrometastasis (pN1 mi): colorectal carcinoma: n = 3, breast: n = 5, other entities together: n = 5).

While the meaning of micrometastasis in axillary lymph nodes is undebated and thus integrated in the TNM system, the prognostic value of this finding for other entities remains unclear. However, the WHO suggests a classification scheme for these.

We will now start to collect follow-up results for all patients in this study to conclude how to deal with these findings in future.